Riskpilot← Back to searchSign inGet full accessMEDI PARTNER AS
ASActiveOrg 965165991Tomteveien 33, 1618 FredrikstadWholesale of pharmaceutical and medical goods · NACE 4646Est. 199233 employees
Revenue 2024
NOK 167,7M
+7% vs 2023
EBITDA margin
2.2%
-55% vs 2023
Equity ratio
24.8%
Financial strength
Net profit 2024
NOK 3,1M
-49% vs 2023
| Revenue | NOK 167,7M | +7% |
| EBITDA | NOK 3,7M | -55% |
| Net profit | NOK 3,1M | -49% |
| Total assets | NOK 81,6M | +0% |
| Equity | NOK 20,2M | +0% |
| Employees | 33 | — |
Legal name
MEDI PARTNER AS
Org number
965165991
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
18. oktober 1992
Share capital
NOK 2 400 000
Employees
33 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og to styremedlemmer i fellesskap.
Company purpose
Handel og engrosvirksomhet. I tillegg er selskapets formål å drive butikkhandel med medisinske og ortopediske artikler.
Address
Tomteveien 33, 1618 Fredrikstad
Phone
+4769367800
Email
post@norengros.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 80 237 | 81 567 | 92 269 | 102 047 | 106 544 | 110 010 | 115 751 | 126 832 | 141 404 | 150 726 | 150 507 | 156 449 | 222 013 | 244 754 | 479 899 | 157 070 | 167 712 |
| Staff expenses | −0 | −8 997 | −11 263 | −11 683 | −13 177 | −14 035 | −13 971 | −15 090 | −16 106 | −19 404 | −20 618 | −21 123 | −21 309 | −21 788 | −19 662 | −22 357 | −19 925 | −19 639 |
| EBITDA | 0 | 6 632 | 7 405 | 8 193 | 9 204 | 9 647 | 11 725 | 13 087 | 11 827 | 12 704 | 13 751 | 13 606 | 12 675 | 37 467 | 42 466 | 134 925 | 8 264 | 3 726 |
| Depreciation & amort. | −0 | −42 | −53 | −287 | −697 | −919 | −914 | −890 | −1 001 | −387 | −327 | −511 | −747 | −661 | −635 | −1 517 | −776 | −610 |
| EBIT | 0 | 6 590 | 7 352 | 7 906 | 8 507 | 8 728 | 10 811 | 12 196 | 10 826 | 12 317 | 13 424 | 13 096 | 11 927 | 36 806 | 41 831 | 133 408 | 7 488 | 3 116 |
| Net financials | 0 | 114 | 123 | 45 | 152 | 78 | 94 | 93 | 91 | 122 | 11 | 188 | 260 | 15 | −554 | 2 658 | 354 | 866 |
| Profit before tax | 0 | 6 704 | 7 475 | 7 951 | 8 659 | 8 806 | 10 905 | 12 290 | 10 916 | 12 439 | 13 435 | 13 284 | 12 188 | 36 821 | 41 277 | 136 066 | 7 842 | 3 982 |
| Tax | −0 | 1 884 | 2 109 | 2 242 | 2 436 | 2 483 | 3 071 | 3 326 | 2 983 | 3 121 | 3 232 | 3 071 | 2 681 | 8 121 | 9 103 | 29 949 | 1 822 | 897 |
| Net profit | 0 | 4 820 | 5 366 | 5 709 | 6 222 | 6 323 | 7 835 | 8 964 | 7 933 | 9 318 | 10 202 | 10 213 | 9 506 | 28 700 | 32 174 | 106 118 | 6 020 | 3 085 |
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | 24 564 | 28 179 | 32 951 | 38 802 | 40 273 | 39 061 | 40 124 | 42 485 | 46 595 | 54 327 | 50 376 | 52 802 | 72 704 | 109 042 | 185 425 | 81 231 | 81 597 |
| Equity | — | 7 342 | 8 459 | 9 901 | 11 623 | 10 146 | 9 881 | 9 844 | 10 677 | 10 395 | 13 597 | 12 616 | 13 122 | 41 822 | 27 996 | 49 114 | 20 134 | 20 219 |
| Long-term debt | 0 | 356 | 0 | 0 | 42 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 16 866 | 19 721 | 23 051 | 27 138 | 30 126 | 29 180 | 30 280 | 31 808 | 36 200 | 40 730 | 37 761 | 39 680 | 30 882 | 81 045 | 136 311 | 61 097 | 61 378 |
| Total debt | 0 | 17 222 | 19 721 | 23 051 | 27 179 | 30 126 | 29 180 | 30 280 | 31 808 | 36 200 | 40 730 | 37 761 | 39 680 | 30 882 | 81 045 | 136 311 | 61 097 | 61 378 |
EBITDA margin
2.2%
This company
15.8%
Market median
-86% vs market
20072024
Equity ratio
24.8%
This company
38.2%
Market median
-35% vs market
20072024
Return on equity
15.3%
This company
18.4%
Market median
+17% vs market
20072024
Net profit margin
1.8%
This company
8.1%
Market median
-78% vs market
20072024
Asset turnover
2.06×
This company
1.12×
Market median
+84% vs market
20072024
Debt / equity
3.04×
This company
0.62×
Market median
-390% vs market
20072024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
- Annual report 2007Filed via Brønnøysundsregistrene · Period 2007-01-01 – 2007-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LA Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Medi Partner Holding As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Medi Partner Holding As
MEDI PARTNER AS Board members of MEDI PARTNER AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lise Andrea Setterberg Nossen | Chief Executive Officer | 0 companies |
| Tom Kristoffersen | Board of Directors | 0 companies |
| Mona Wenzell | Board of Directors | 0 companies |
| Lars Erik Andersen | Chairman | 0 companies |
| Oddvar Rune Melleby | Board of Directors | 0 companies |